4//SEC Filing
HENNER DENNIS 4
Accession 0001012975-15-000017
CIK 0001337553other
Filed
Jan 11, 7:00 PM ET
Accepted
Jan 12, 9:44 AM ET
Size
20.8 KB
Accession
0001012975-15-000017
Insider Transaction Report
Form 4
LIPTAK ROBERT
10% Owner
Transactions
- Sale
Common Stock
2015-01-08$31.11/sh−175,000$5,444,250→ 3,324,259 total
HENNER DENNIS
Director10% Owner
Transactions
- Sale
Common Stock
2015-01-08$31.11/sh−175,000$5,444,250→ 3,324,259 total
STEINMETZ MICHAEL
10% Owner
Transactions
- Sale
Common Stock
2015-01-08$31.11/sh−175,000$5,444,250→ 3,324,259 total
WHEELER KURT
10% Owner
Transactions
- Sale
Common Stock
2015-01-08$31.11/sh−175,000$5,444,250→ 3,324,259 total
Clarus Lifesciences II, L.P.
10% Owner
Transactions
- Sale
Common Stock
2015-01-08$31.11/sh−175,000$5,444,250→ 3,324,259 total
Clarus Ventures II GP, L.P.
10% Owner
Transactions
- Sale
Common Stock
2015-01-08$31.11/sh−175,000$5,444,250→ 3,324,259 total
Clarus Ventures II, LLC
10% Owner
Transactions
- Sale
Common Stock
2015-01-08$31.11/sh−175,000$5,444,250→ 3,324,259 total
GALAKATOS NICHOLAS
10% Owner
Transactions
- Sale
Common Stock
2015-01-08$31.11/sh−175,000$5,444,250→ 3,324,259 total
Simon Nicholas
10% Owner
Transactions
- Sale
Common Stock
2015-01-08$31.11/sh−175,000$5,444,250→ 3,324,259 total
Footnotes (2)
- [F1]The price reflected is the weighted-average sale price for shares sold. The range of sale prices for the transactions reported was $31.00 to $31.25 per shares. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F2]Securities held of record by Clarus Lifesciences II, L.P. ("Clarus"). Clarus Ventures II GP, L.P. (the "GPLP"), as the sole general partner of Clarus, may be deemed to beneficially own certain of the shares held of record by Clarus. The GPLP disclaims beneficial ownership of all shares held of record by Clarus in which the GPLP does not have an actual pecuniary interest. Clarus Ventures II, LLC (the "GPLLC"), as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held of record by Clarus. Each of Messrs. Galakatos, Henner, Liptak, Simon, Steinmetz and Wheeler, as individual Managing Directors of the GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Each of the GPLLC and Messrs. Galakatos, Henner, Liptak, Simon, Steinmetz and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which it or he, as applicable, does not have an actual pecuniary interest.
Documents
Issuer
AERIE PHARMACEUTICALS INC
CIK 0001337553
Entity typeother
Related Parties
1- filerCIK 0001249153
Filing Metadata
- Form type
- 4
- Filed
- Jan 11, 7:00 PM ET
- Accepted
- Jan 12, 9:44 AM ET
- Size
- 20.8 KB